Causes cell death by specific inhibition of DNA synthesis. This action causes regressions in chronic myeloid leukemia and other malignancies and psoriasis. The S-phase-specific action of hydroxyurea can deplete bone marrow precursor cells associated with megaloblastic changes.
In treatment of myeloproliferative disorders including chronic granulocytic leukaemia, polycythemia vera and essential thrombocytosis. Melanoma, metastatic or inoperable carcinoma of ovary. In combination with radiotherapy in carcinoma of cervix, head, neck and lung.
After oral administration it is readily absorbed from GI tract. Hydroxyurea readily crosses blood brain barrier.
Severe anaemia, marked bone marrow depression.
Nausea, vomiting, rash, bone marrow depression is the major toxic effect. Alopecia, stomatitis, dysuria. Inflamation and increased pigmentation may occur in areas exposed to radiation. Rare neurological disturbances.
Monitor hepatic and renal functions. Haematological monitoring (including bone marrow). Premenopausal women, recent x-ray or cytotoxic therapy.
Lab tests : May cause increase in serum uric acid, creatinine and BUN levels.
Dosage regimens have not been established.
500mg capsule, 20 capsules per box (10 caps x 2 strips).
|
|||||||||||||||||||||||||||||||||
|
Disclaimer
: This guide is provided for information purposes only, and for use
of a registered medical practitioner or a hospital or a laboratory only.
The authors, webmaster, or respective references / links are no way
responsible for the content of the information. Although a concerted
effort has been made to ensure the validity of the information contained
in this document, we give no
assurance for the accuracy of the information in this documents. |
|||||||||||||||||||||||||||||||||